Thyrocare decided Diwali came early — not for patients, but shareholders. 🎆 A 2:1 bonus issue, a ₹7 interim dividend, and some serious self-praise about “affordable diagnostics for all.” Rahul Guha even dropped a Mandela quote before slipping in Six Sigma dreams and Tanzanian ambitions. Somewhere between HbA1c data and GLP-1 drugs, the call turned into a TED Talk on healthcare philosophy. Read on — it gets spicy when margins start flexing and radiology stops being the ugly stepchild.
2. At a Glance
Revenue up 22% – CFO swore it’s not COVID base math, just pure blood-test brilliance.
EBITDA margin 34.8% – Every pip squeezed like a lemon in a pathology beaker.
PAT up 82% YoY – Thyroid tests printing profits faster than printers print reports.
Gross margin 72% – Because needles don’t cost as much as servers.
Cash ₹190 Cr+ – Company so liquid it could test itself for hydration.
Bonus 2:1 + ₹7 Dividend – Diwali gift before anyone asked “What about us?”
3. Management’s Key Commentary
“Bonus shares 2:1 to commemorate 25 years of Thyrocare.” (Because nothing says ‘Silver Jubilee’ like free paper wealth.)
“Our non-COVID growth over 4 years is 19% CAGR.” (When COVID left the room, we finally found real growth.)
“We’ve achieved 100% NABL accreditation across all labs.” (Translation: we can now officially brag in every investor meet.)
“Complaint rate down from 11.8% to 3.8%, aiming for Six Sigma.” (Somewhere a consultant just got goosebumps.) 😏
“We processed 53.3 million tests, serving 5 million patients.” (Or as they call it internally — ‘5 million pricks.’)
“Tanzania business up 30% QoQ, breakeven in 18–24 months.” (Even Africa’s veins aren’t safe from Thyrocare’s syringes.)
“GLP-1 drugs will drive test demand; we’re launching therapy packages.” (Because what’s weight loss without a full blood panel to prove it?)
